May 14, 2020

RE: Reopening of MTN studies to accrual

Dear Colleagues,

This letter is in follow-up to our letter dated March 18, 2020 announcing a pause in the enrollment of participants onto our MTN studies. We currently have 5 studies which were recruiting on March 18, 2020 which have been paused including:

- MTN-034 (REACH)
- MTN-039
- MTN-042 (Deliver)
- MTN-045 (Cupid)

In addition, MTN-043 trial (B-Protected) which had not been activated on March 18, 2020 has continued to move forward with the activation requirements,

MTN leadership recognizes that COVID-19 has created a great deal of uncertainty related to travel and transport of study participants, safety of the study staff, local regulations governing research activities and limited availability of transport for study products and shipment of laboratory samples. It is also clear that conditions related to COVID-19 and the protective measures instituted by local governments and regulatory agencies will differ from site to site. **The MTN is now lifting the blanket pause in study enrollment across our trials. However, the decision regarding when study enrollment can begin at individual sites will be governed by the management team for each study and will be contingent upon local advisories related to research activity and orders to stay at home.**

We greatly appreciate the tremendous efforts made by our study teams who have continued follow-up of participants enrolled in REACH, DESIRE (MTN-035) and Deliver. We also applaud the progress made toward the activation of sites which will participate in Deliver and B-Protected. COVID-19 will be with us in the months ahead, but our efforts to stop the spread of HIV must continue. We look forward to moving forward with the completion of our studies while protecting the safety of our global network of participants and study team members.

Respectfully,

Sharon L. Hillier, PhD
Richard L. Sweet Professor of Reproductive Infectious Diseases, Vice Chair Faculty Affairs, Department of Obstetrics, Gynecology and Reproductive Sciences University of Pittsburgh School of Medicine Magee Womens Research Institute Principal Investigator, Microbicides Trials Network

Jared Baeten, MD, PhD
Vice Chair, Department of Global Health Professor, Departments of Global Health, Medicine, and Epidemiology Director, UW/Fred Hutch Center for AIDS Research (CFAR) Co-Director, International Clinical Research Center University of Washington Co-Principal Investigator, Microbicides Trials Network